Zacks: Analysts Expect Avalo Therapeutics, Inc. (NASDAQ:AVTX) Will Announce Earnings of -$0.14 Per Share

Wall Street analysts predict that Avalo Therapeutics, Inc. (NASDAQ:AVTXGet Rating) will report earnings per share of ($0.14) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Avalo Therapeutics’ earnings, with estimates ranging from ($0.16) to ($0.12). Avalo Therapeutics posted earnings per share of ($0.32) in the same quarter last year, which indicates a positive year over year growth rate of 56.3%. The company is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Avalo Therapeutics will report full-year earnings of ($0.56) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.48). For the next fiscal year, analysts forecast that the business will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.42) to ($0.30). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Avalo Therapeutics.

Avalo Therapeutics (NASDAQ:AVTXGet Rating) last posted its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Avalo Therapeutics had a negative net margin of 1,563.10% and a negative return on equity of 285.61%.

Several research analysts recently weighed in on the company. Zacks Investment Research upgraded Avalo Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 7th. Royal Bank of Canada cut their price target on Avalo Therapeutics from $5.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, March 3rd. Jefferies Financial Group cut Avalo Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $5.00 to $0.75 in a research note on Thursday, March 3rd. Finally, Oppenheimer restated a “buy” rating and issued a $5.00 price target on shares of Avalo Therapeutics in a research note on Friday, January 7th.

Shares of Avalo Therapeutics stock opened at $0.60 on Friday. Avalo Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $3.70. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 1.42. The stock has a 50 day moving average of $0.74 and a 200 day moving average of $1.42.

In other news, Director Armistice Capital, Llc acquired 150,000 shares of the company’s stock in a transaction on Thursday, February 17th. The shares were bought at an average price of $0.81 per share, with a total value of $121,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have acquired 1,052,300 shares of company stock worth $790,354. Corporate insiders own 45.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP purchased a new position in shares of Avalo Therapeutics during the third quarter worth about $1,747,000. Alliancebernstein L.P. purchased a new position in shares of Avalo Therapeutics during the third quarter worth about $42,000. Two Sigma Investments LP acquired a new stake in Avalo Therapeutics in the third quarter valued at about $1,598,000. Integral Health Asset Management LLC acquired a new stake in Avalo Therapeutics in the third quarter valued at about $3,543,000. Finally, Voya Investment Management LLC acquired a new stake in Avalo Therapeutics in the third quarter valued at about $48,000. 75.81% of the stock is currently owned by hedge funds and other institutional investors.

About Avalo Therapeutics (Get Rating)

Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.

Further Reading

Get a free copy of the Zacks research report on Avalo Therapeutics (AVTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.